Prostate Cancer Trial, Recruiting (NCT02971085)

Prostate Cancer Trial, Recruiting NCT02971085 Sponsor: Seoul National University Hospital Condition: Prostate Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT02971085 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Prostate Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Men under 80 years of age
People who have been diagnosed with a specific type of prostate cancer (adenocarcinoma) confirmed through a biopsy that took at least 10 tissue samples
People whose PSA blood test result before biopsy was 10 ng/ml or lower
People whose PSA density (a calculation based on PSA level and prostate size) was below 0.15 ng/ml/ml
People whose cancer is at an early stage, classified as T1 or T2a (confirm with trial site)
People whose biopsy showed a Gleason score of 6 or lower, which indicates a less aggressive cancer
People where no more than 2 of the tissue samples taken during biopsy showed cancer
People where cancer made up no more than 20% of any single tissue sample
People whose prostate MRI scan (at 1.5T or 3T strength) did not show a high-suspicion area known as a PIRADS 5 lesion
People who are willing and able to attend all required follow-up visits
People with early-stage T1a or T1b disease that has been confirmed through a systematic ultrasound-guided biopsy of at least 10 cores (confirm with trial site)

Who may not be able to join:

People who have previously received any treatment for prostate cancer

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 15 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Chang Wook Jeong, M.D, Ph.D, Seoul National University Hospital

Phone: +82-2-2072-3899

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT02971085

Sponsor: Seoul National University Hospital

Phase: Not Applicable

Status: Recruiting

Condition: Prostate Cancer

Trial contact: +82-2-2072-3899

More information: https://clinicaltrials.gov/study/NCT02971085

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

Men under 80 years of age
People who have been diagnosed with a specific type of prostate cancer (adenocarcinoma) confirmed through a biopsy that took at least 10 tissue samples
People whose PSA blood test result before biopsy was 10 ng/ml or lower
People whose PSA density (a calculation based on PSA level and prostate size) was below 0.15 ng/ml/ml
People whose cancer is at an early stage, classified as T1 or T2a (confirm with trial site)
People whose biopsy showed a Gleason score of 6 or lower, which indicates a less aggressive cancer
People where no more than 2 of the tissue samples taken during biopsy showed cancer
People where cancer made up no more than 20% of any single tissue sample
People whose prostate MRI scan (at 1.5T or 3T strength) did not show a high-suspicion area known as a PIRADS 5 lesion
People who are willing and able to attend all required follow-up visits
People with early-stage T1a or T1b disease that has been confirmed through a systematic ultrasound-guided biopsy of at least 10 cores (confirm with trial site)

Who may not be able to join:

People who have previously received any treatment for prostate cancer

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 15 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Seoul National University Hospital

Registry

ClinicalTrials.gov

Start date

1 December 2016

Est. completion

1 January 2022

Where this trial is recruiting

🇰🇷 South Korea

Primary endpoints

Pathological reclassification

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov